What I mean is that renal, although lower revenue, would have a very high margin because there would not be all the carry-on trying to get the hospitals etc testing to the protocol in lymphedema, liaising with private payors , trying to standardise policies - that will really cut into the bottom-line in the first couple of years.
Ann: Market Update - Executing Towards Profitability in Oncology, page-102
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
